Announcements Trials

Browse Landscape

Phase

Phase NA 19 Phase 2 10 Phase 3 4 Phase 2/3 3 Phase EARLY_PHASE1 1 Phase 1 1

Status

Completed 9 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 281 Carcinoma, Non-Small-Cell Lung 251 Leukemia, Myeloid, Acute 189 Breast Neoplasms 151 Melanoma 150 Neoplasm Metastasis 148 Multiple Myeloma 127 Recurrence 123 Colorectal Neoplasms 119 Lymphoma, Non-Hodgkin 113 Lymphoma 112 Leukemia, Lymphocytic, Chronic, B-Cell 107 Pancreatic Neoplasms 99 Ovarian Neoplasms 99 Precursor Cell Lymphoblastic Leukemia-Lymphoma 91 Leukemia 85 Prostatic Neoplasms 83 Lung Neoplasms 81 Lymphoma, Large B-Cell, Diffuse 77 Squamous Cell Carcinoma of Head and Neck 76 Glioblastoma 73 Carcinoma, Renal Cell 72 Myelodysplastic Syndromes 67 Lymphoma, Follicular 65 Brain Neoplasms 60 Lymphoma, Mantle-Cell 55 Sarcoma 53 Stomach Neoplasms 52 Head and Neck Neoplasms 52 Triple Negative Breast Neoplasms 49

Interventions

Methylphenidate 1 5,10-dihydro-5-methylphenazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Terminated × Fatigue × Clear all

NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated

3 enrolled 7 charts

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡